vTv Therapeutics (NASDAQ:VTVT) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of vTv Therapeutics (NASDAQ:VTVT) from a hold rating to a sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Several other research firms also recently commented on VTVT. Weiss Ratings downgraded shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Zacks Research raised shares of vTv Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. Lifesci Capital raised shares of vTv Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 2nd. BTIG Research reiterated a “buy” rating and set a $57.00 price target on shares of vTv Therapeutics in a research note on Wednesday, October 14th. Finally, HC Wainwright decreased their price objective on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $55.83.

vTv Therapeutics Trading Up 1.0%

NASDAQ VTVT opened at $25.81 on Friday. The company has a fifty day simple moving average of $30.80 and a 200 day simple moving average of $33.82. vTv Therapeutics has a 12-month low of $19.80 and a 12-month high of $44.00. The company has a market cap of $101.69 million, a P/E ratio of -24.35 and a beta of 0.21.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). Sell-side analysts predict that vTv Therapeutics will post -2.35 EPS for the current year.

About vTv Therapeutics

vTv Therapeutics Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer’s disease.